Tesamorelin side effects: why monitor blood sugar and IGF-1?

Which product does this guide describe?

This guide uses the US prescribing information for Egrifta WR, a prescription tesamorelin medicine for excess abdominal fat in adults with HIV-associated lipodystrophy. It is not indicated for weight-loss management. The clinical safety studies used an earlier Egrifta formulation; the label explains the basis for applying those findings to WR. Products and regulatory rules elsewhere may differ.1

Why check blood sugar?

Tesamorelin can cause glucose intolerance: blood sugar is not handled as well as usual. The label recommends checking glucose before and periodically during treatment. In its clinical-trial summary, 5% of the active-treatment group versus 1% of the placebo group reached an HbA1c threshold of at least 6.5% by week 26. HbA1c reflects average blood glucose over the preceding months. These are trial-defined results over that period, not a prediction or lifetime risk for a particular person.1

What is IGF-1 and why does it matter?

Tesamorelin stimulates the release of growth hormone, which can increase IGF-1, a protein involved in growth signalling. The label calls for IGF-1 monitoring and says the consequences of prolonged elevations are unknown. A higher number is a biological response; it does not by itself prove better muscle function, health or longevity. A clinician interprets results in context.1

What side effects were reported?

The label describes injection-site reactions, joint pain, swelling and other fluid-related effects, and hypersensitivity reactions such as rash. A reported event does not always mean the medicine caused it, and trial rates may differ from everyday care. The label’s warning and its adverse-reaction table give different injection-site percentages without clearly explaining the distinction, so we do not present a single comparison here. Prompt medical attention is important for a suspected serious allergic reaction.1

Who needs particular care?

The US label lists pregnancy, active cancer, certain disruption of the pituitary signalling system and known allergy as contraindications for Egrifta WR. It describes additional considerations for a history of cancer and some medicines, including steroid replacement. These are product-specific reasons for clinical assessment, not a complete checklist for every formulation. Tell the care team about medicines, medical history and pregnancy or breastfeeding.1

The Egrifta WR label recommends monitoring for possible interactions with medicines processed by certain liver enzymes, including some anticonvulsants and ciclosporin. It also says people receiving glucocorticoid replacement for diagnosed adrenal insufficiency may need their replacement plan adjusted after starting Egrifta WR. The prescribing team makes that decision; do not change steroid or other prescribed medicines on your own.2

What remains unknown?

The label states that long-term cardiovascular safety has not been established. A reduction in fat around organs does not prove fewer heart attacks or longer life. See what the visceral-fat trial measured and what happened when participants stopped. A healthcare professional can discuss how benefits, monitoring and possible harms fit a particular situation.1